# Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial

> **NCT05652673** · NA · RECRUITING · sponsor: **Erasmus Medical Center** · enrollment: 80 (estimated)

## Conditions studied

- Melanoma Stage IV
- Melanoma Stage III
- Immunotherapy
- Toxicity, Drug

## Interventions

- **DRUG:** nivolumab

## Key facts

- **NCT ID:** NCT05652673
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-01
- **Primary completion:** 2025-12-01
- **Final completion:** 2029-12-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05652673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05652673, "Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial". Retrieved via AI Analytics 2026-09-05 from https://api.ai-analytics.org/clinical/NCT05652673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*